000			02301 a2200673 4500
005			20250516064128.0
264		0	_c20130701
008			201307s 0 0 eng d
022			_a1778-7254
024	7		_a10.1016/j.jbspin.2011.10.001 _2doi
040			_aNLM _beng _cNLM
100	1		_aToussirot, Éric
245	0	0	_aDevelopment of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series. _h[electronic resource]
260			_bJoint bone spine _cOct 2012
300			_a457-63 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntirheumatic Agents _xtherapeutic use
650	0	4	_aArthritis, Juvenile _xdrug therapy
650	0	4	_aArthritis, Psoriatic _xdrug therapy
650	0	4	_aArthritis, Rheumatoid _xdrug therapy
650	0	4	_aChild
650	0	4	_aColitis, Ulcerative _xchemically induced
650	0	4	_aCrohn Disease _xchemically induced
650	0	4	_aEtanercept
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aFrance _xepidemiology
650	0	4	_aHumans
650	0	4	_aImmunoglobulin G _xtherapeutic use
650	0	4	_aIncidence
650	0	4	_aInflammatory Bowel Diseases _xchemically induced
650	0	4	_aInfliximab
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aReceptors, Tumor Necrosis Factor _xtherapeutic use
650	0	4	_aRetrospective Studies
650	0	4	_aRheumatic Diseases _xdrug therapy
650	0	4	_aSpondylitis, Ankylosing _xdrug therapy
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
650	0	4	_aYoung Adult
700	1		_aHouvenagel, Éric
700	1		_aGoëb, Vincent
700	1		_aFouache, Damien
700	1		_aMartin, Antoine
700	1		_aLe Dantec, Philippe
700	1		_aDernis, Emmanuelle
700	1		_aWendling, Daniel
700	1		_aAnsemant, Thiphaine
700	1		_aBerthelot, Jean-Marie
700	1		_aBader-Meunier, Brigitte
700	1		_aKantelip, Bernadette
773	0		_tJoint bone spine _gvol. 79 _gno. 5 _gp. 457-63
856	4	0	_uhttps://doi.org/10.1016/j.jbspin.2011.10.001 _zAvailable from publisher's website
999			_c21316843 _d21316843